

Received Date : 19-Dec-2015

Revised Date : 04-Aug-2016

Accepted Date : 10-Aug-2016

Article type : Original Paper

## **mTOR Regulates the Expression of DNA Damage Response Enzymes in Long-lived Snell Dwarf, GHRKO and PAPPA-KO mice**

Graham Dominick\*, Jacqueline Bowman\*, Xinna Li<sup>†</sup>, Richard A. Miller<sup>†‡</sup> and Gonzalo G. Garcia<sup>†</sup>

*\*Department of Molecular, Cellular, and Developmental Biology, University of Michigan College of Literature, Science and the Arts. <sup>†</sup>Department of Pathology, University of Michigan School of Medicine. <sup>‡</sup>University of Michigan Geriatrics Center, Ann Arbor, Michigan 48109, r*

**Author to whom correspondence should be addressed:** Gonzalo G. Garcia

Room 3005 BSRB, Box 2200, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA

Phone: (734) 936-2164; Fax: (734) 936-9220; E-mail: gonzola@umich.edu

**Running Title:** mTOR controls MGMT and NDRG1 protein expression

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/accel.12525](https://doi.org/10.1111/accel.12525)

This article is protected by copyright. All rights reserved

## Abstract

Studies of the mTOR pathway have prompted speculation that diminished mTOR complex-1 (mTORC1) function may be involved in controlling the aging process. Our previous studies have shown diminished mTORC1 activity in tissues of three long-lived mutant mice: Snell dwarf mice, growth hormone receptor gene disrupted mice (GHRKO) and, in the current paper, mice deficient in the pregnancy-associated protein-A (PAPPA-KO). The ways in which lower mTOR signals slow aging and age-related diseases are, however, not well characterized. Here we show that Snell, GHRKO, and PAPPA-KO mice express high levels of two proteins involved in DNA repair, O-6-methylguanine-DNA methyltransferase (MGMT) and N-myc downstream-regulated gene 1 (NDRG1). Furthermore, we report that lowering mTOR enhances MGMT and NDRG1 protein expression via posttranscriptional mechanisms. We show that the CCR4-NOT complex, a posttranscriptional regulator of gene expression, is downstream of the mTORC1 pathway and may be responsible for the upregulation of MGMT and NDRG1 in all three varieties of long-lived mice. Our data thus suggest a novel link between DNA repair and mTOR signaling via posttranscriptional regulation involving specific alteration in the CCR4-NOT complex, whose modulation could control multiple aspects of the aging process.

## Introduction

Several lines of evidence have implicated the mechanistic target of rapamycin (mTOR) in the regulation of aging. In lower organisms, such as *Caenorhabditis elegans* and *Drosophila melanogaster*, inactivation or reduction of mTOR activity results in life extension [1]. In addition, reduction of mTOR activity by rapamycin [2] or reduction in expression of mTOR kinase by hypomorphic mTOR alleles [3-5] can increase mouse life span. mTOR is a serine/threonine kinase that forms the catalytic core of at least 2 complexes, mTOR complex-1

(mTORC1) and mTOR complex-2 (mTORC2). In vivo, the phosphorylation of ribosomal protein S6 (pS6<sub>(235)</sub>) and initiation factor 4E-binding protein (p4E-BP1<sub>(37)</sub>) are markers of mTORC1 activity. Phosphorylation of AKT at Ser-473 (pAKT<sub>(473)</sub>), Ser-450 (pAKT<sub>(450)</sub>) and the N-myc downstream-regulated gene (pNDRG<sub>(346)</sub>) are considered markers of mTORC2 activity. We have recently studied the phosphorylation status of these substrates in the Snell and GHRKO mice, two long lived genetic models, and found tissue specific reduction in mTORC1 activity as well as alteration in mTORC2 activity [6]. Interestingly, neither mTORC1 nor mTORC2 was altered in mice with liver-specific deletion of GHR, mice in which lifespan is normal despite dramatically lower levels of serum IGF-1 [6, 7]. The metalloproteinase PAPP-A is thought to act by regulating local IGF-1 action through degradation of some IGF-1 binding proteins, particularly IGF-BP4 [8]. PAPP-A deletion can extend both mean and maximum lifespan by 20–40%, with a reduced incidence of spontaneous tumors, without modulation of serum levels of GH or IGF-1. Effects of PAPP-A-KO on mTORC1 and mTORC2 have not yet been reported. The mechanistic links between GH/IGF-1 regulation and prolongation of lifespan in these three varieties of mice are not well understood.

O-6-methylguanine-DNA methyltransferase (MGMT) is an enzyme involved in the direct reversal of DNA damage in vitro and postmitotic cells in vivo by methylating agents used clinically for chemotherapy [9, 10]. It has been suggested that MGMT may play a role in regulating mouse life span [11], but it is not known whether long lived mice, such as Snell, GHRKO and PAPP-A-KO, have altered expression of MGMT. Higher expression of NDRG1, a protein of unknown function, can promote MGMT protein stability and activity in human glioma cells by mechanisms that include protein interactions and preferential translation [12, 13]. Therefore, understanding the signaling pathways regulating MGMT and NDRG1 may provide insights into resistance to DNA damage, chemotherapy and the aging process. We hypothesized that higher expression of MGMT and NDRG1 may be a common feature shared by Snell, GHRKO, and PAPP-A-KO mice, and that mTOR activity could be a key upstream regulator of MGMT and NDRG1 expression. Microarray analysis of the mRNA gene expression profiles of many different models of slow aging mice have not led to a consensus on common pathway(s) central to the aging process, including mice whose lifespan has been increased by mTOR reduction by drugs [14] or dietary interventions [15]. However, it is plausible that improved DNA repair may be one important common feature [11]. Discrepancy between mRNA levels and

protein expression in many genes complicates interpretation of mRNA patterns in tissues of slow-aging mice, and it is likely that gene regulation by posttranscriptional mechanisms, including changes in mRNA stability [16, 17], regulation by microRNAs [18, 19] and sequestration to P and ER bodies, may contribute to altered levels of DNA repair proteins in slow-aging mice.

The CCR4-NOT complex is a key regulator of mRNA stability, microRNA function and preferential translation, and functions as a check point in the control of translation and protein degradation [20, 21]. The CCR4-NOT complex is comprised of at least 10 subunits, but there is limited information about the function of individual components of the complex in mammals. Recent reports using in vitro methods have helped to clarify some functional roles of CNOT components [22-24]. Mice in which CNOT6 has been deleted are viable but, with exception of some bone abnormalities, do not have obvious changes in phenotype. However, CNOT3 heterozygous mice [25] display some phenotypes reminiscent of Snell [26, 27], Ames dwarf [27], GHRKO [28] and PAPPA-KO mice [29], including higher insulin sensitivity, improved glucose tolerance and higher oxygen consumption. Here, we present evidence suggesting that Snell, GHRKO, and PAPPA-KO mice express high levels of NDRG1 and MGMT proteins that are under the control of mTORC1 activity, and that this regulation involves posttranscriptional mechanisms that may depend on alteration of the CCR4-NOT complex.

## Results

### **Multiple models of slow aging, including PAPPA-KO mice, show lower mTORC1 activity.**

We have recently reported that Snell and GHRKO mice show reduced mTORC1 activity in multiple tissues, accompanied by changes in both fasting and food-induced mTORC2 activity [6]. To see if PAPPA-KO mice showed similar changes in mTORC1 and mTORC2 activity, we measured phosphorylation of mTORC1 substrates pS6<sub>(S235/236)</sub> [referred to as pS6 in figures and text], p4E-BP1<sub>(T37/46)</sub> [termed p4E-BP1 in figures and text] and mTORC2 substrates pAKT<sub>(T450)</sub> and pNDRG1<sub>(T346)</sub> [termed pNDRG1 in figures and text], either after 18 hours of fasting or after 18 hours of fasting followed by 6 hours of access to food [6]. Figure 1A shows a representative western blot for liver, and Figure 1B shows mean values from 3 independent experiments using

at least 8 mice per group. We found no significant sex effects (half of the mice were males) on any of the measures reported in this paper (data not shown). Supplemental Table 1 shows parallel experiments for muscle, heart, and kidney of PAPP-A-KO mice for the mTORC1 substrates, with estimates of fold induction as well as the results of ANOVA testing significance of the effects of genotype (G), nutritional conditions (fasting versus feeding, N) and GxN interactions (Int). We found that PAPP-A-KO mice show lower levels of pS6 and p4E-BP1, independent of nutritional status, in all four tissues tested (Figure 1 and supplemental Table 1). Two-factor ANOVA confirmed the significant effect of the PAPP-A deletion (genotype effects: WT > KO) and feeding (nutritional effects: fed > fasting), without evidence for interaction. The results are similar to our findings for Snell and GHRKO mice [6]. We found no differences in the expression of total S6 or 4E-BP protein in any of the groups (data not shown).

Results for mTORC2 substrates pAKT<sub>(450)</sub> and pNDRG are shown in Figure 1A and B for liver, and are summarized in supplemental Table 2 for all four tissues. Consistent with Snell and GHRKO mice [6], fasted PAPP-A-KO mice have higher mTORC2 activity, and this activity decreases in response to feeding in PAPP-A-KO but not in WT control mice (Figure 1). Statistical analysis using ANOVA confirmed that feeding has significant interaction effects for pAKT<sub>(450)</sub> and pNDRG (Figure 1B and supplemental Table 2). The overall results suggest that PAPP-A-KO, Snell and GHRKO mice share a common regulatory mechanism for mTOR activity and signaling that includes tissue specific declines in mTORC1 activity and differential regulation of mTORC2 activity.

### **Snell, GHRKO and PAPP-A-KO mice show higher NDRG1 and MGMT protein expression, but no changes in NDRG1 or MGMT mRNA expression.**

Using a rabbit monoclonal from Cell Signaling (D6C2) we noted an increase in levels of total NDRG1 protein expression in liver of PAPP-A-KO mice (Figure 1A). Higher NDRG1 expression has been associated with enhanced DNA repair through increased MGMT protein stability/activity [13]. We therefore measured NDRG1 and MGMT protein expression in liver, skeletal muscle (upper leg) and kidney from our three slow-aging mice models fed ad lib. The

right panels of Figure 2 show representative results from liver tissue in Snell (Figure 2A), GHRKO (Figure 2B) and PAPP4-KO (Figure 2C). NDRG1 and MGMT protein expression was increased by 2x to 3x in each kind of slow-aging mouse.

To assess if higher protein levels were the result of upregulation of NDRG1 and MGMT mRNA transcripts we performed qRT-PCR for both genes in liver. In contrast to the protein data, there were no differences in the levels of NDRG1 and MGMT mRNA in any of the mouse models (Figure 2 right panels). We confirmed these results using 3 other differently designed probes for MGMT and NDRG1 (data not shown). We also found no differences in the GAPDH mRNA expression (supplemental Figure 1). This suggested that discrepancies between protein expression and mRNA levels might reflect differential posttranscriptional regulation of MGMT and NDRG1 in slow aging mice.

### **mTOR signaling regulates NDRG1 and MGMT protein expression but not their mRNA expression**

In some human cell lines, rapamycin (mTOR inhibitor) can enhance MGMT protein expression, and this increase is the result of preferential translation of MGMT transcripts [12]. mTOR can also regulate stress resistance by preferential translation of certain mRNAs [30], including ATF-4 [31]. Hence, we hypothesized that changes in mTOR function in Snell, GHRKO and PAPP4-KO mice could increase NDRG1 and MGMT via a posttranscriptional pathway. To test this idea we treated mouse fibroblasts from a genetically heterogeneous stock of mice [2] with rapamycin for 48 hours and analyzed the expression of NDRG1 and MGMT using western blots and qRT-PCR. The data (Figure 3) show that rapamycin enhances NDRG1 and MGMT protein expression, at a concentration that impairs phosphorylation of the mTORC1 substrates 4E-BP1 and S6. Statistical analysis confirmed significant increases in NDRG1 and MGMT protein in fibroblasts treated for 48 hr with rapamycin (Figure 3A middle panel). Parallel mRNA analysis found no differences in NDRG1 and MGMT mRNA expression (or in GAPDH mRNA) in fibroblasts exposed to rapamycin for 24 or 72 hr (not shown). These results suggest that mTOR regulates fibroblast NDRG1 and MGMT protein expression through a posttranscriptional mechanism. However, extended rapamycin treatments can diminish expression and phosphorylation of some of the mTORC2 substrates (pAKT/AKT in Figure 3A and [5, 32]), suggesting that lower mTORC2 function may, in part, be responsible for some of the effects we

see in MGMT and NDRG1 expression. The overall results suggest that mTOR plays a key role, but more work will be needed to determine the specific role of each complex (mTORC1 and mTORC2) in these animals.

We also tested the *in vivo* effects of rapamycin on NDRG1 and MGMT in liver. A single rapamycin injection increases NDRG1 and MGMT protein expression in liver (Figure 3B). Rapamycin leads to the expected reduction in mTORC1 activity (indicated by pS6), and no apparent changes in mTORC2 activity (as measured by phosphorylation of AKT<sub>450</sub> and AKT<sub>473</sub>). Statistical analysis showed significant increases in NDRG1 and MGMT protein expression by rapamycin. Consistent with the fibroblast experiments, there are no significant changes in NDRG1, MGMT mRNA levels. The *in vivo* results suggest that mTOR can regulate NDRG1 and MGMT expression through posttranscriptional mechanisms, and that lower mTORC1 activity in Snell, GHRKO and PAPPa-KO mice may upregulate MGMT and NDRG1. However, Schreiber et al. [33] have suggested that rapamycin effects on mTORC2 signaling may be difficult to detect, and we cannot rule out the idea that mTORC2 could also play an important role in regulating MGMT and NDRG1 expression in the slow-aging mice.

### **Snell, GHRKO and PAPPa-KO mice show similar alterations in the expression of components of the CCR4-NOT complex**

To see if changes in components of the CCR4-NOT complex could be involved in differential posttranscriptional regulation we tested expression of CNOT1, CNOT3, CNOT6 and CNOT6L in liver of Snell, GHRKO and PAPPa-KO mice. CNOT3 was selected because its decline leads to some features shared with slow-aging mice [25]. CNOT6 and CNOT6L were tested because they may regulate DNA repair [34]. As shown in Figure 4, CNOT1 and CNOT3 levels are lower, and CNOT6 and CNOT6L higher, in liver from each variety of slow-aging mice.

CNOT1 and CNOT3 mRNA CT values are higher in Snell and GHRKO liver (Figure 4) in good agreement with the protein data. In contrast, we found no changes in the CNOT6 mRNA levels with respect to WT controls and, unexpectedly, found a significant reduction in CNOT6L mRNA (Figure 4A/B). The results of CNOT6 and CNOT6L do not correspond with the level of their protein expression. We do not know the reason for this discrepancy but, it suggests that CNOT components may also themselves be subject to posttranscriptional regulation. CNOT4, which does not associate with CCR4-NOT in mammals and does not regulate mRNA stability or

translation [21], did not differ between long-lived and littermate control mice (supplemental Figure 2).

Feeding mice increases CNOT3 expression [25]. Interestingly, provision of food after a period of fasting increased CNOT3 and CNOT6L mRNA expression in control mice, but not in Snell littermates (Figure 4D). This results could be explained by a higher level of mTORC1 activity in control mice (WT) that could contribute to the differential upregulation of CNOT3 and CNOT6L mRNA in response to food.

### **Rapamycin inhibition of mTORC1 activity mimics some of the changes in the CCR4-CNOT complex expression found in Snell, GHRKO and PAPPa-KO mice.**

To test the hypothesis that mTOR can regulate the expression of components of the CCR4-NOT complex, we treated primary mouse fibroblasts with rapamycin and analyzed the expression of CNOT1, CNOT3, CNOT6 and CNOT6L using western blots and qRT-PCR. Rapamycin significantly decreased CNOT1 and CNOT3 protein expression, and enhanced expression of CNOT6L; however CNOT6 protein was not affected (Figure 5A). Rapamycin significantly diminished CNOT1, CNOT3 and CNOT6L mRNA but not CNOT6 mRNA (supplemental Figure 3). This pattern of consistent changes in protein and mRNA data for CNOT1, CNOT3 and CNOT6L is similar to that noted for Snell, GHRKO and PAPPa-KO mice (Figures 4). For in vivo confirmation, we treated mice with rapamycin for 48 hours and analyzed the expression of CCR4-NOT components in liver. Rapamycin reduced CNOT1 and CNOT3 and enhanced CNOT6L, but did not change CNOT6 (Figure 5B), consistent with the fibroblast results. Thus CNOT1, CNOT3 and CNOT6L are under the control of mTOR signaling at the level of transcription and posttranscriptional mechanisms. In contrast, CNOT6 is not affected by rapamycin at the dose and time used.

### **CNOT3 regulates NDRG1 and MGMT protein expression**

To see if CNOT3 or CNOT6L might be involved in mTORC1 regulation of NDRG1 and MGMT protein expression, we transfected mouse fibroblasts with constructs overexpressing human CNOT3 and CNOT6L (GFP-CNOT3, GFP-CNOT6L). Human CNOT3 and CNOT6L share 95-99 % of their amino acid sequence with their mouse homologs and thus are likely to function in



mouse cells. In addition, we tested the effects of reduction in lower CNOT3 and CNOT6L expression using silencing constructs (shRNAs) tailored to their respective mouse genes. Mouse fibroblasts were transfected, and efficiency measured using green fluorescent protein (supplemental Figure 4A). Quantification showed a range from 10 to 30% efficiency, depending on the construct (data not shown). Immunoblotting shows the expected increases or declines in CNOT3 and CNOT6L protein at 72 hours after transfection (supplemental Figure 4B). Overexpression of CNOT3 led to reduction in NDRG1 and MGMT protein expression, while CNOT3 downregulation increased NDRG1 and MGMT (Figure 6A, top panel). Statistical analysis confirmed significant effects in NDRG1 and MGMT expression by CNOT3 (Figure 6B). Neither overexpression nor reduction of CNOT6L protein affected NDRG1 or MGMT protein expression. Furthermore, changes in CNOT3 and CNOT6L did not affect mTOR activity (no changes in phosphorylation of S6 or AKT<sub>(473)</sub>), suggesting that CCR4-NOT is downstream of mTOR in regulating NDRG1 and MGMT expression (Figure 6A). These results suggest that CNOT3 is a posttranscriptional regulator of NDRG1 and MGMT protein expression and that declines in CNOT3 in Snell, GHRKO and PAPPa-KO mice may be involved in the enhanced expression of these DNA repair enzymes.

## Discussion

Our data showing reduction of mTORC1 in multiple tissues of Snell, GHRKO [6] and now PAPPa-KO mice support the hypothesis that mTORC1 controls some of the intracellular events leading to life span extension in mammals. It is still unclear, however, how lower mTORC1 action might lead to improved health and better survival in aging mice. Many lines of evidence [35] suggest that increases in stress resistance [36], including better DNA repair [37], may be involved in longevity and disease resistance. This idea is now supported by our observation of increases in MGMT and NDRG1, which are involved in direct reversal of DNA damage, in multiple tissues of three stocks of slow-aging mice. Our evidence that reducing mTORC1 activity leads to enhancement in the MGMT and NDRG1 protein expression, both in cultured cells and in mice, strongly suggests a link between mTOR signaling and the DNA repair pathway [38] that may be central in delaying the aging process. Our data also suggest a possible

involvement of mTORC1-mediated alteration in post-transcriptional regulation of MGMT and NDRG1 translation via changes in elements of the CCR4-CNOT complex.

Comparative microarray analysis between several genetic models [39, 40], pharmacological interventions [14, 41] and dietary interventions [42] known to extend life span has not revealed consistent shared features at the level of transcriptional changes, including mRNA levels for enzymes from the DNA repair response such as MGMT and NDRG1. These observations are consistent with our qRT-PCR analysis, which showed no significant changes in NDRG1 and MGMT mRNA expression in the Snell, GHRKO and PAPP-A-KO mice with respect to controls (Figure 2). The discrepancy between the mRNA and protein levels suggested that a posttranscriptional mechanism may be involved in the physiology of these mouse models and in the control of longevity and age-dependent diseases.

Our data suggest that the CCR4-NOT complex, a key regulator of posttranscriptional gene expression, may link mTOR changes to DNA repair in these slow-aging mice. Snell, GHRKO and PAPP-A-KO mice show a consistent pattern of changes in CNOT1, CNOT3, CNOT6, and CNOT6L, both in cultured cells and in intact mice, a pattern recapitulated in control cells and in control mice by short-term exposure to rapamycin. Thus regulation of key CCR4-NOT expression components seems to be under the control of mTORC1 (such as CNOT1, CNOT3 and CNOT6L shown in Figure 5), and down regulation of CNOT3 expression seems to upregulate NDRG1 and MGMT protein expression (Figure 6). The CCR4-NOT complex has been studied in yeast [21], but little is known about the function of individual components in higher organisms such as mice [21].

CCR4-NOT components, including CNOT3, CNOT6 and CNOT6L, can regulate mRNA stability, microRNA function, localization to the P/Stress bodies and preferential translation [21]. However, this regulation involves the interaction of a wide range of tissue specific mRNA binding proteins [43, 44], and thus more multifaceted work will be needed to determine how the changes in CNOT protein levels shown in Figure 4 contribute to protection against age-related changes in specific cell and tissue types. Recent studies in Snell, GHRKO and PAPP-A-KO mice have shown a common physiology that may be control aging rate and multiple age-related diseases [27, 45, 46]. These mice all exhibit high insulin sensitivity and an increased oxygen consumption with high levels of peroxisome proliferator-associated receptor  $\gamma$  coactivator 1

(Pgc1 $\alpha$ ) from oxidative phosphorylation [47, 48]. Similarly, CNOT3 heterozygous mice [25] have been shown to have increased insulin sensitivity, oxidative phosphorylation (including higher Pgc1 $\alpha$  expression) and oxygen consumption. Our data suggest that CCR4-NOT complex, including CNOT3, could be one of the signaling pathways downstream of mTORC1 regulating some of these changes (Figure 2). Therefore, it would be interesting to test if declines in CNOT3 (such as in the CNOT3 heterozygous [25]), along with changes in other components of the CCR4-NOT, could themselves extend life span. It would also be interesting to define what specific mechanism the CCR4-NOT components are using to enhance expression of the MGMT and NDRG1 DNA repair genes, such as regulation by microRNA or preferential translation (or both). Because many of the CCR4-NOT components are essential for development, future studies of CCR4-NOT and its effects on DNA repair and the aging process would require the use of conditional knockouts triggered in adulthood. Of particular interest in the aging processes would be CCR4-NOT components that affect posttranscriptional mechanisms, such as CNOT6 and CNOT6L. Alternatively, when available, the analysis of CNOT6 and CNOT6L +/- heterozygous mice would also shed some light on possible functions of CNOT in aging. On the other hand, it is also possible that changes in proteasomal function in slow aging mice could contribute to the elevation of MGMT, NDRG1 and CNOT6L [49-51].

Increases in CNOT6L have been suggested to increase the ATM-dependent DNA repair response [34]. In this context, it will be interesting to determine if tissues from slow aging mice have increases in other DNA repair mechanisms, or, alternatively, if being heterozygous for CNOT components would lead to changes in DNA repair that may affect the aging process. Overall, the data presented here suggest a signaling pathway in which alterations in mTOR, including declines in mTORC1, lead to alterations in posttranscriptional regulation of gene expression, including genes involved in DNA repair, via changes in composition and function of the CCR4-NOT complex.

## Material and Methods

## **Reagents, mice, and fasting and feeding conditions**

Snell (DW) were produced as previously described [6]. Breeding stock for GHRKO mice were provided by provided by Andrzej Bartke (Southern Illinois University, IL) and John Kopchick (Edison Biotechnology Institute of Ohio University, OH) and produced as previously described [6]. Breeding stock for PAPPa-KO mice were provided by Cheryl Conover (Mayo Clinic, Rochester, MN) and produced as previously described [52]. DW, GHRKO and PAPPa-KO mice were used at ages from 5-6 months. Genetically heterogeneous mice (UM-HET3) ranging from 10 to 12 months of age were produced by a cross between two different F1 parents: (BALB/cByJ × C57BL/6J)F1 mothers and (C3H/HeJ × DBA/2J)F1 fathers as previously described [2]. All experiments were approved by the University of Michigan University Committee on Use and Care of Animals. Sentinel animals were examined quarterly for evidence of viral infection; all tests were negative. Mice used were fed ad lib or, as indicated in the text, fasted for 18 hours (fasted mice) followed by ad lib feeding with a regular chow diet for 6 hours (fed mice). All mice had free access to water during the course of treatments. Chemical reagents were purchased from Sigma ([www.sigmaldrich.com](http://www.sigmaldrich.com)). Rapamycin was purchased from LC laboratories ([www.lclabs.com](http://www.lclabs.com)). The source of antibodies and phospho-specific antibodies are described in supplemental Table 3. Primary mouse fibroblasts from UM-HET3 mice were cultured as described [46]. Clones corresponding to human CNOT3 (pT7-EGFP-HsNOT3, addgene plasmid 37369) and CNOT6L (pT7-EGFP-HsNOT6L, addgene plasmid 37372) were a gift from Elisa Izaurralde (Max Planck Institute for Developmental Biology, Germany). The shRNA for mouse CNOT3 (NM\_146176.2) and mouse CNOT6L (NM\_144910.1) were purchased from Genecopoeia ([www.genecopoeia.com](http://www.genecopoeia.com)). Plasmid transfections were carried out with Lipofectamine 3000 as described by the manufacturer ([www.thermofisher.com](http://www.thermofisher.com)). qRT-PCR were performed as described [53]. Probes were manufactured by IDT ([www.idtdna.com](http://www.idtdna.com)) corresponding to the sequences shown in supplemental Table 4.

## **Rapamycin treatments, tissue preparation, western blot analysis**

Acute rapamycin treatments in UM-HET3 mouse fibroblasts were performed at 0.1  $\mu$ M. In vivo rapamycin treatments were performed with a single intraperitoneal injection of rapamycin at 5 mg/kg to each UM-HET mouse (ranging from 10 to 12 months of age) as previously described

[54]. Tissues from each mouse were collected, frozen with liquid nitrogen and stored at  $-70^{\circ}\text{C}$ . The tissue samples were then processed to obtain cell lysates for Western blots [6] or qRT-PCR analysis [53]. Mouse fibroblasts were collected and lysed, and equal amounts of protein were loaded for western blot analysis [46]

### **Statistical analysis**

Unless indicated otherwise, results are presented as mean  $\pm$  standard error of the mean (SEM). Statistical tests for genotype, fasting and fed conditions (nutritional), or interaction effects were assessed by two-way analysis of variance (ANOVA) using  $p = 0.05$  as the threshold for significant effects. To compare specific effects between groups, an unpaired t-test was used with  $p = 0.05$  as the criterion for significance.

**Acknowledgements:** We thank Dr. Andrzej Bartke and John Kopchick for GHRKO breeders and Dr. Cheryl Conover for PAPP A-KO breeders. We thank Dr. David Lombard and Dr. Diane Fingar for comments on the manuscript and Sabrina Van Roekel, Amanda Keedle, and Natalie Perry for expert animal husbandry.

**Funding:** This work was supported by grants from the National Institutes of Health AG019899 and AG024824, and the University of Michigan Paul Glenn Center for the Biology of Aging. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

**Abbreviations:** mTOR, mammalian target of rapamycin; GHRKO, growth hormone receptor deletion mice; PAPP A-KO or KO, pregnancy-associated protein A deletion mice; DW, Snell dwarf mice; MGMT, O-6-methylguanine-DNA methyltransferase; NDRG1, N-myc downstream-regulated gene 1.

## References

1. Sharp ZD, Curiel TJ, Livi CB. Chronic mechanistic target of rapamycin inhibition: preventing cancer to delay aging, or vice versa? *Interdiscip Top Gerontol*. 2013;38:1-16. doi: 10.1159/000343625. PubMed PMID: 23503511.
2. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature*. 2009;460(7253):392-5. PubMed PMID: 19587680.
3. Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. *Cell Rep*. 2013;4(5):913-20. doi: 10.1016/j.celrep.2013.07.030. PubMed PMID: 23994476; PubMed Central PMCID: PMC3784301.
4. Selman C, Tullet JMA, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science (New York, N Y)*. 2009;326(5949):140-4. PubMed PMID: 19797661.
5. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. *Science (New York, N Y)*. 2012;335(6076):1638-43. PubMed PMID: 22461615.
6. Dominick G, Berryman DE, List EO, Kopchick JJ, Li X, Miller RA, et al. Regulation of mTOR activity in Snell dwarf and GH receptor gene-disrupted mice. *Endocrinology*. 2015;156(2):565-75. doi: 10.1210/en.2014-1690. PubMed PMID: 25456069; PubMed Central PMCID: PMC4298324.
7. Bartke A. Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: novel findings. *Aging Cell*. 2008;7(3):285-90. doi: 10.1111/j.1474-9726.2008.00387.x. PubMed PMID: 18346217.
8. Conover CA, Bale LK. Loss of pregnancy-associated plasma protein A extends lifespan in mice. *Aging Cell*. 2007;6(5):727-9. doi: 10.1111/j.1474-9726.2007.00328.x. PubMed PMID: 17681037.
9. Iyama T, Wilson DM, 3rd. DNA repair mechanisms in dividing and non-dividing cells. *DNA Repair (Amst)*. 2013;12(8):620-36. doi: 10.1016/j.dnarep.2013.04.015. PubMed PMID: 23684800; PubMed Central PMCID: PMC3720834.

10. Jiang G, Jiang AJ, Xin Y, Li LT, Cheng Q, Zheng JN. Progression of O(6)-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research. *Mol Biol Rep.* 2014;41(10):6659-65. doi: 10.1007/s11033-014-3549-z. PubMed PMID: 24990698.
11. Meira LB, Calvo JA, Shah D, Klapacz J, Moroski-Erkul CA, Bronson RT, et al. Repair of endogenous DNA base lesions modulate lifespan in mice. *DNA Repair (Amst).* 2014;21:78-86. doi: 10.1016/j.dnarep.2014.05.012. PubMed PMID: 24994062; PubMed Central PMCID: PMC4125484.
12. Smalley S, Chalmers AJ, Morley SJ. mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells. *Mol Cancer.* 2014;13:144. doi: 10.1186/1476-4598-13-144. PubMed PMID: 24909675; PubMed Central PMCID: PMC4061125.
13. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. *Proc Natl Acad Sci U S A.* 2014;111(1):409-14. doi: 10.1073/pnas.1314469111. PubMed PMID: 24367102; PubMed Central PMCID: PMC43890826.
14. Yu Z, Sunchu B, Fok WC, Alshaikh N, Perez VI. Gene expression in the liver of female, but not male mice treated with rapamycin resembles changes observed under dietary restriction. *Springerplus.* 2015;4:174. doi: 10.1186/s40064-015-0909-7. PubMed PMID: 26034704; PubMed Central PMCID: PMC4447730.
15. Swindell WR. Comparative analysis of microarray data identifies common responses to caloric restriction among mouse tissues. *Mech Ageing Dev.* 2008;129(3):138-53. doi: 10.1016/j.mad.2007.11.003. PubMed PMID: 18155270; PubMed Central PMCID: PMC2702675.
16. Brewer G. Messenger RNA decay during aging and development. *Ageing Res Rev.* 2002;1(4):607-25. PubMed PMID: 12208236.
17. Lee EK, Gorospe M. Minireview: posttranscriptional regulation of the insulin and insulin-like growth factor systems. *Endocrinology.* 2010;151(4):1403-8. doi: 10.1210/en.2009-1123. PubMed PMID: 20032049; PubMed Central PMCID: PMC2850238.
18. Bates DJ, Li N, Liang R, Sarojini H, An J, Masternak MM, et al. MicroRNA regulation in Ames dwarf mouse liver may contribute to delayed aging. *Aging Cell.* 2010;9(1):1-18. doi: 10.1111/j.1474-9726.2009.00529.x. PubMed PMID: 19878148; PubMed Central PMCID: PMC2844644.

19. Liang R, Khanna A, Muthusamy S, Li N, Sarojini H, Kopchick JJ, et al. Post-transcriptional regulation of IGF1R by key microRNAs in long-lived mutant mice. *Aging Cell*. 2011;10(6):1080-8. doi: 10.1111/j.1474-9726.2011.00751.x. PubMed PMID: 21967153; PubMed Central PMCID: PMC3587961.
20. Inada T, Makino S. Novel roles of the multi-functional CCR4-NOT complex in post-transcriptional regulation. *Front Genet*. 2014;5:135. doi: 10.3389/fgene.2014.00135. PubMed PMID: 24904636; PubMed Central PMCID: PMC3587961.
21. Shirai YT, Suzuki T, Morita M, Takahashi A, Yamamoto T. Multifunctional roles of the mammalian CCR4-NOT complex in physiological phenomena. *Front Genet*. 2014;5:286. doi: 10.3389/fgene.2014.00286. PubMed PMID: 25191340; PubMed Central PMCID: PMC3587961.
22. Larabee RN, Hosni-Ahmed A, Workman JJ, Chen H. Ccr4-not regulates RNA polymerase I transcription and couples nutrient signaling to the control of ribosomal RNA biogenesis. *PLoS Genet*. 2015;11(3):e1005113. doi: 10.1371/journal.pgen.1005113. PubMed PMID: 25815716; PubMed Central PMCID: PMC3587961.
23. Okada H, Schittenhelm RB, Straessle A, Hafen E. Multi-functional regulation of 4E-BP gene expression by the Ccr4-Not complex. *PLoS One*. 2015;10(3):e0113902. doi: 10.1371/journal.pone.0113902. PubMed PMID: 25793896; PubMed Central PMCID: PMC3587961.
24. Rodriguez-Gil A, Ritter O, Hornung J, Stekman H, Kruger M, Braun T, et al. HIPK family kinases bind and regulate the function of the CCR4-NOT complex. *Mol Biol Cell*. 2016. doi: 10.1091/mbc.E15-09-0629. PubMed PMID: 27122605.
25. Morita M, Oike Y, Nagashima T, Kadomatsu T, Tabata M, Suzuki T, et al. Obesity resistance and increased hepatic expression of catabolism-related mRNAs in Cnot3<sup>+/-</sup> mice. *EMBO J*. 2011;30(22):4678-91. doi: 10.1038/emboj.2011.320. PubMed PMID: 21897366; PubMed Central PMCID: PMC3587961.
26. Bartke A, Brown-Borg H. Life extension in the dwarf mouse. *Curr Top Dev Biol*. 2004;63:189-225. doi: 10.1016/S0070-2153(04)63006-7. PubMed PMID: 15536017.
27. Boylston WH, DeFord JH, Papaconstantinou J. Identification of longevity-associated genes in long-lived Snell and Ames dwarf mice. *Age (Dordr)*. 2006;28(2):125-44. doi:



10.1007/s11357-006-9008-6. PubMed PMID: 19943135; PubMed Central PMCID: PMCPMC2464723.

28. Brown-Borg HM, Bartke A. GH and IGF1: roles in energy metabolism of long-living GH mutant mice. *J Gerontol A Biol Sci Med Sci.* 2012;67(6):652-60. doi: 10.1093/gerona/gls086. PubMed PMID: 22466316; PubMed Central PMCID: PMCPMC3348496.
29. Hill CM, Arum O, Boparai RK, Wang F, Fang Y, Sun LY, et al. Female PAPP-A knockout mice are resistant to metabolic dysfunction induced by high-fat/high-sucrose feeding at middle age. *Age (Dordr).* 2015;37(3):9765. doi: 10.1007/s11357-015-9765-1. PubMed PMID: 25953669; PubMed Central PMCID: PMCPMC4424199.
30. Reiter AK, Anthony TG, Anthony JC, Jefferson LS, Kimball SR. The mTOR signaling pathway mediates control of ribosomal protein mRNA translation in rat liver. *Int J Biochem Cell Biol.* 2004;36(11):2169-79. doi: 10.1016/j.biocel.2004.04.004. PubMed PMID: 15313464.
31. Ait Ghezala H, Jolles B, Salhi S, Castrillo K, Carpentier W, Cagnard N, et al. Translation termination efficiency modulates ATF4 response by regulating ATF4 mRNA translation at 5' short ORFs. *Nucleic Acids Res.* 2012;40(19):9557-70. doi: 10.1093/nar/gks762. PubMed PMID: 22904092; PubMed Central PMCID: PMCPMC3479206.
32. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell.* 2006;22(2):159-68. doi: 10.1016/j.molcel.2006.03.029. PubMed PMID: 16603397.
33. Schreiber KH, Ortiz D, Academia EC, Anies AC, Liao CY, Kennedy BK. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. *Aging Cell.* 2015;14(2):265-73. doi: 10.1111/accel.12313. PubMed PMID: 25652038; PubMed Central PMCID: PMCPMC4364838.
34. Sanchez-Perez I, Manguan-Garcia C, Menacho-Marquez M, Murguia JR, Perona R. hCCR4/cNOT6 targets DNA-damage response proteins. *Cancer Lett.* 2009;273(2):281-91. doi: 10.1016/j.canlet.2008.08.026. PubMed PMID: 18818012.
35. Lombard DB, Miller RA. Ageing: Sorting out the sirtuins. *Nature.* 2012;483(7388):166-7. doi: 10.1038/nature10950. PubMed PMID: 22367538.
36. Murakami S. Stress resistance in long-lived mouse models. *Exp Gerontol.* 2006;41(10):1014-9. doi: 10.1016/j.exger.2006.06.061. PubMed PMID: 16962277.

37. De Luca G, Ventura I, Sanghez V, Russo MT, Ajmone-Cat MA, Cacci E, et al. Prolonged lifespan with enhanced exploratory behavior in mice overexpressing the oxidized nucleoside triphosphatase hMTH1. *Aging Cell*. 2013;12(4):695-705. doi: 10.1111/accel.12094. PubMed PMID: 23648059.
38. Strozyk E, Kulms D. The role of AKT/mTOR pathway in stress response to UV-irradiation: implication in skin carcinogenesis by regulation of apoptosis, autophagy and senescence. *Int J Mol Sci*. 2013;14(8):15260-85. doi: 10.3390/ijms140815260. PubMed PMID: 23887651; PubMed Central PMCID: PMC3759859.
39. Svensson J, Sjogren K, Faldt J, Andersson N, Isaksson O, Jansson JO, et al. Liver-derived IGF-I regulates mean life span in mice. *PLoS One*. 2011;6(7):e22640. doi: 10.1371/journal.pone.0022640. PubMed PMID: 21799924; PubMed Central PMCID: PMC3143189.
40. Hofmann JW, Zhao X, De Cecco M, Peterson AL, Pagliaroli L, Manivannan J, et al. Reduced expression of MYC increases longevity and enhances healthspan. *Cell*. 2015;160(3):477-88. doi: 10.1016/j.cell.2014.12.016. PubMed PMID: 25619689; PubMed Central PMCID: PMC4624921.
41. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. *Aging Cell*. 2014;13(3):468-77. doi: 10.1111/accel.12194. PubMed PMID: 24341993; PubMed Central PMCID: PMC4032600.
42. Bartke A, Masternak MM, Al-Regaiey KA, Bonkowski MS. Effects of dietary restriction on the expression of insulin-signaling-related genes in long-lived mutant mice. *Interdiscip Top Gerontol*. 2007;35:69-82. doi: 10.1159/000096556. PubMed PMID: 17063033.
43. Temme C, Simonelig M, Wahle E. Deadenylation of mRNA by the CCR4-NOT complex in *Drosophila*: molecular and developmental aspects. *Front Genet*. 2014;5:143. doi: 10.3389/fgene.2014.00143. PubMed PMID: 24904643; PubMed Central PMCID: PMC4033318.
44. Reese JC. The control of elongation by the yeast Ccr4-not complex. *Biochim Biophys Acta*. 2013;1829(1):127-33. doi: 10.1016/j.bbagr.2012.09.001. PubMed PMID: 22975735; PubMed Central PMCID: PMC3545033.

45. Brown-Borg HM. Longevity in mice: is stress resistance a common factor? *Age (Dordr)*. 2006;28(2):145-62. doi: 10.1007/s11357-006-9003-y. PubMed PMID: 19943136; PubMed Central PMCID: PMCPMC2464727.
46. Murakami S, Salmon A, Miller RA. Multiplex stress resistance in cells from long-lived dwarf mice. *FASEB J*. 2003;17(11):1565-6. doi: 10.1096/fj.02-1092fje. PubMed PMID: 12824282.
47. Stauber AJ, Brown-Borg H, Liu J, Waalkes MP, Laughter A, Staben RA, et al. Constitutive expression of peroxisome proliferator-activated receptor alpha-regulated genes in dwarf mice. *Mol Pharmacol*. 2005;67(3):681-94. doi: 10.1124/mol.104.007278. PubMed PMID: 15576629.
48. Corton JC, Brown-Borg HM. Peroxisome proliferator-activated receptor gamma coactivator 1 in caloric restriction and other models of longevity. *J Gerontol A Biol Sci Med Sci*. 2005;60(12):1494-509. PubMed PMID: 16424281.
49. Wang M, Miller RA. Augmented autophagy pathways and MTOR modulation in fibroblasts from long-lived mutant mice. *Autophagy*. 2012;8(8):1273-4. doi: 10.4161/auto.20917. PubMed PMID: 22653655; PubMed Central PMCID: PMCPMC3679241.
50. Zhang Y, Manning BD. mTORC1 signaling activates NRF1 to increase cellular proteasome levels. *Cell Cycle*. 2015;14(13):2011-7. doi: 10.1080/15384101.2015.1044188. PubMed PMID: 26017155; PubMed Central PMCID: PMCPMC4613906.
51. Zhang Y, Nicholatos J, Dreier JR, Ricoult SJ, Widenmaier SB, Hotamisligil GS, et al. Coordinated regulation of protein synthesis and degradation by mTORC1. *Nature*. 2014;513(7518):440-3. doi: 10.1038/nature13492. PubMed PMID: 25043031; PubMed Central PMCID: PMCPMC4402229.
52. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Fuchtbauer EM, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. *Development*. 2004;131(5):1187-94. doi: 10.1242/dev.00997. PubMed PMID: 14973274.
53. Li X, Bartke A, Berryman DE, Funk K, Kopchick JJ, List EO, et al. Direct and indirect effects of growth hormone receptor ablation on liver expression of xenobiotic metabolizing genes. *Am J Physiol Endocrinol Metab*. 2013;305(8):E942-50. doi:

10.1152/ajpendo.00304.2013. PubMed PMID: 23941873; PubMed Central PMCID: PMC3798695.

54. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. *Diabetes*. 2010;59(6):1338-48. doi: 10.2337/db09-1324. PubMed PMID: 20299475; PubMed Central PMCID: PMC2874694.

## Figure Legends

### Figure 1. mTORC activity in liver of PAPP-A mice.

A) Representative western blots showing the phosphorylation of S6, 4E-BP1, AKT and NDRG1 in liver samples from PAPP-A-KO (KO) and control littermates (WT) under fasting (Fasted) or fed (Fed) conditions. B) Quantification of pS6, p4E-BP1, pAKT(450) and pNDRG1 phosphorylation as ratios to the level of the corresponding protein. All bar graphs represent the mean  $\pm$  SEM from a total of 8 mice (4 females and 4 males) per group and are normalized with respect to ratio of 1 in fasted WT for each protein. The asterisk (\*) indicates statistical significance relative to the fasting WT from each group.

### Figure 2. Snell mice (DW), GHRKO and PAPP-A (KO) mice show higher NDRG1 and MGMT protein expression but does not significant alters their mRNA expression

A) Representative western blots showing NDRG1 and MGMT expression in Snell mice (DW) from liver (left). Quantification in liver, skeletal muscle and kidney (middle panels) is shown as mean  $\pm$  SEM from 3 experiments, using a total of at least 12 mice (6 females and 6 males) per group, using normalization as described in Figure 1. The qRT-PCR CT dotplot values for NDRG1 and MGMT expression are shown in right panels. Each symbol represents an individual mouse. Horizontal lines show mean  $\pm$  SEM from a total of 16 mice (8 females and 8 males) per group. The asterisk (\*) indicates statistical significance relative to the WT controls of each group. B) Results for GHRKO mice from at least 11 mice (6 females and 5 males) per group for

protein expression (middle panels) and for qRT-PCR using 8 mice (4 females and 4 males) per group (right panels). C) Results for PAPPA-KO (KO) mice from at least 8 mice (4 females and 4 males) per group and qRT-PCR using at least 10 mice (5 females and 5 males) per group.

**Figure 3. Rapamycin enhances MGMT and NDRG1 protein expression but does not significantly alter their mRNA expression**

A) Representative western blots showing pS6, p4E-BP1 and pAKT phosphorylation (in parallel to total S6, 4E-BP1 and AKT protein), as well as NDRG1 and MGMT expression in mouse fibroblasts, either untreated (-, Control) or treated with Rapamycin (+, Rapa). Bar graphs represent the mean  $\pm$  SEM from 6 independent experiments normalized with respect to WT controls. The CT value dotplots show mRNA levels from 6 independent experiments. The (\*) indicates statistical significance. B) Analysis of rapamycin effects in liver of UM-HET mice from at least 8 mice per group.

**Figure 4. Livers of Snell mice (DW), GHRKO and PAPPA-KO (KO) mice show declines in CNOT1 and CNOT3 accompanied by increases in CNOT6L and CNOT6 protein.**



A) Left panels represent western blots of CCR4-CNOT complex components in Snell mice (DW) and control mice (WT) from liver. Quantification shown as mean  $\pm$  SEM of 3 experiments in middle panels from a total of 12 mice (6 females and 6 males) per group using normalization as described in Figure 1. Right panel shows the qRT-PCR CT values for CCR4-CNOT mRNA levels in livers from at least 14 mice (7 females and 7 males) per group. The (\*) indicates statistical significance relative to the WT controls of each group. B) Data for protein levels in GHRKO mice (left and middle panels), using 6 mice (3 females and 3 males) per group. qRT-PCR CT data (right panels) from at least 12 mice (6 females and 6 males) per group. C) Data for protein in PAPPA-KO (KO) mice, using 9 mice (5 females and 4 males) per group. D) Effect of fasting and feeding on mRNA expression of CNOT3 and CNOT6L in livers of Snell (DW) and WT control mice from at least 6 mice (1/2 females and 1/2 males) per group. The (\*) indicates statistical significance relative to Snell (DW).

**Figure 5. Rapamycin treatment decreases CNOT1 and CNOT3 expression and increases CNOT6L protein expression, but does not affect CNOT6 expression.**


A) Representative western blots showing expression of components of the CCR4-CNOT complex in mouse fibroblasts untreated (-, control) or treated with Rapamycin (+, Rapa). Bar graphs represent the mean  $\pm$  SEM from a total of 6 independent experiments normalized with respect to WT controls. The (\*) indicates statistical significance. B) Analysis of rapamycin effects on CNOT components in mouse livers, either untreated (-, Control) or treated with Rapamycin (+, Rapa) from at least 8 mice per group (50% males).

**Figure 6. Effect of overexpressing or downregulating CNOT3 and CNOT6L protein on NDRG1 and MGMT protein expression in mouse fibroblasts.**

A) Representative western blots for NDRG1 and MGMT expression after 72 hours of transfection, together with pS6, pAKT, CNOT1, CNOT6 in the same samples. B) Quantification of the NDRG1 and MGMT protein expression after each transfection shown as mean  $\pm$  SEM normalized to controls for 6 independent experiments; the (\*) indicates statistical significance.




acel\_12525\_f1.tif




acel\_12525\_f2.tif








acel\_12525\_f3.tif



acel\_12525\_f4.tif



acel\_12525\_f5.tif



acel\_12525\_f6.tif